Pharyngitis Market

Market Overview:

The 7 major pharyngitis markets reached a value of US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.29% during 2024-2034.

The pharyngitis market has been comprehensively analyzed in IMARC's new report titled "Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pharyngitis refers to a medical condition that causes inflammation or infection of the pharynx, which is the part of the throat located behind the nasal cavity and mouth. The most common symptom of the ailment is a sore throat that may be accompanied by pain or discomfort while swallowing. Numerous other indications of this disease include redness and swelling of the throat, inflammation of the tonsils, swollen lymph nodes in the neck, hoarseness or a scratchy voice, coughing, runny nose, sneezing, body aches, headaches, fever, etc. The diagnosis of pharyngitis usually involves a physical examination, evaluation of symptoms, and sometimes a throat swab to determine the presence of bacteria or viruses. Additionally, several blood tests may be performed to assess the general health of the patient and check for indications of the infection. These investigations can measure various parameters, such as white blood cell count and C-reactive protein (CRP) levels. A healthcare provider may further conduct polymerase chain reaction (PCR) testing to detect the genetic material of the pathogen causing the condition.

The increasing cases of viral and bacterial infections, which invade the healthy cells in the lining of the throat and tonsils, leading to inflammation and irritation, are primarily driving the pharyngitis market. In addition to this, the rising prevalence of exposure to dry air, smoking, pollution, etc., or numerous other environmental irritants, like allergens and strong fumes, that can directly damage the pharyngeal tissues, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), antivirals, antibiotics, etc., to treat the ailment or manage the disease symptoms is further bolstering the market growth. Apart from this, the inflating application of throat lozenges or sprays, which contain numbing agents like benzocaine and menthol to relieve discomfort and pain by soothing the irritated tissues, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of photobiomodulation therapy, since it uses light-emitting diodes or low-level lasers to stimulate cellular function in patients and promote healing, is expected to drive the pharyngitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pharyngitis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for pharyngitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pharyngitis market in any manner.

Key Highlights:

• Pharyngitis affects roughly 11 million people in the United States each year.
• The National Ambulatory Medical Care Survey revealed 6.2 to 9.7 million visits to primary care medical professionals, clinics, and emergency departments annually for children with pharyngitis, and more than 5 million visits per year for adults.
• The highest burden of illness is found in children and young adults, with 50% of cases diagnosed between the ages of 5 and 24 years.
• Viruses are the most common causes of pharyngitis, accounting for 25–45% of all cases.
• During the winter, streptococcal infection will account for 15-25% of all instances of pharyngitis in children.

Drugs:

MOXATAG is a penicillin-class antibiotic used to treat tonsillitis and/or pharyngitis caused by Streptococcus pyogenes (S. pyogenes) in adults and children aged 12 and up. MOXATAG should be taken once a day, within an hour of finishing a meal, for ten days. To effectively treat tonsillitis and/or pharyngitis caused by S. pyogenes, a full 10-day course of medication should be completed.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the pharyngitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the pharyngitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pharyngitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the pharyngitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the pharyngitis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the pharyngitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of pharyngitis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pharyngitis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of pharyngitis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with pharyngitis across the seven major markets?
• What is the size of the pharyngitis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of pharyngitis?
• What will be the growth rate of patients across the seven major markets?

Pharyngitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for pharyngitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pharyngitis market?
• What are the key regulatory events related to the pharyngitis market?
• What is the structure of clinical trial landscape by status related to the pharyngitis market?
• What is the structure of clinical trial landscape by phase related to the pharyngitis market?
• What is the structure of clinical trial landscape by route of administration related to the pharyngitis market?